Literature DB >> 22351072

Synaptic dysfunction in Parkinson's disease.

Barbara Picconi1, Giovanni Piccoli, Paolo Calabresi.   

Abstract

Activity-dependent modifications in synaptic efficacy, such as long-term depression (LTD) and long-term potentiation (LTP), represent key cellular substrates for adaptive motor control and procedural memory. The impairment of these two forms of synaptic plasticity in the nucleus striatum could account for the onset and the progression of motor and cognitive symptoms of Parkinson's disease (PD), characterized by the massive degeneration of dopaminergic neurons. In fact, both LTD and LTP are peculiarly controlled and modulated by dopaminergic transmission coming from nigrostriatal terminals. Changes in corticostriatal and nigrostriatal neuronal excitability may influence profoundly the threshold for the induction of synaptic plasticity, and changes in striatal synaptic transmission efficacy are supposed to play a role in the occurrence of PD symptoms. Understanding of these maladaptive forms of synaptic plasticity has mostly come from the analysis of experimental animal models of PD. A series of cellular and synaptic alterations occur in the striatum of experimental parkinsonism in response to the massive dopaminergic loss. In particular, dysfunctions in trafficking and subunit composition of glutamatergic NMDA receptors on striatal efferent neurons contribute to the clinical features of the experimental parkinsonism. Interestingly, it has become increasingly evident that in striatal spiny neurons, the correct assembly of NMDA receptor complex at the postsynaptic site is a major player in early phases of PD, and it is sensitive to distinct degrees of DA denervation. The molecular defects at the basis of PD progression may be not confined just at the postsynaptic neuron: accumulating evidences have recently shown that the genes linked to PD play a critical role at the presynaptic site. DA release into the synaptic cleft relies on a proper presynaptic vesicular transport; impairment of SV trafficking, modification of DA flow, and altered presynaptic plasticity have been described in several PD animal models. Furthermore, an impaired DA turnover has been described in presymptomatic PD patients. Thus, given the pathological events occurring precociously at the synapses of PD patients, post- and presynaptic sites may represent an adequate target for early therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351072     DOI: 10.1007/978-3-7091-0932-8_24

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  82 in total

1.  Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson's disease.

Authors:  Marta Carmo; Francisco Q Gonçalves; Paula M Canas; Jean-Pierre Oses; Francisco D Fernandes; Filipe V Duarte; Carlos M Palmeira; Angelo R Tomé; Paula Agostinho; Geanne M Andrade; Rodrigo A Cunha
Journal:  Br J Pharmacol       Date:  2019-08-01       Impact factor: 8.739

Review 2.  A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.

Authors:  Giulia Ambrosi; Silvia Cerri; Fabio Blandini
Journal:  J Neural Transm (Vienna)       Date:  2014-01-01       Impact factor: 3.575

Review 3.  Autophagy in synaptic development, function, and pathology.

Authors:  Dan-Na Shen; Li-Hui Zhang; Er-Qing Wei; Yi Yang
Journal:  Neurosci Bull       Date:  2015-07-02       Impact factor: 5.203

Review 4.  Neurotrophin Signaling and Stem Cells-Implications for Neurodegenerative Diseases and Stem Cell Therapy.

Authors:  Subrata Pramanik; Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2016-11-05       Impact factor: 5.590

Review 5.  Deep brain stimulation: are astrocytes a key driver behind the scene?

Authors:  Albert J Fenoy; Laurent Goetz; Stéphan Chabardès; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2014-01-24       Impact factor: 5.243

6.  STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.

Authors:  Pradeep K Kurup; Jian Xu; Rita Alexandra Videira; Chimezie Ononenyi; Graça Baltazar; Paul J Lombroso; Angus C Nairn
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

7.  C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons.

Authors:  Wangchao Xu; Jin Xu
Journal:  J Neurosci       Date:  2018-07-23       Impact factor: 6.167

Review 8.  Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi; Timothy L Megraw; Jennifer Curtiss; Mahsa Shirani Faradonbeh; Pooneh Vaziri; Mohammad Hossein Nasr-Esfahani
Journal:  Neuromolecular Med       Date:  2015-11-26       Impact factor: 3.843

9.  Selective effects of dopamine depletion and L-DOPA therapy on learning-related firing dynamics of striatal neurons.

Authors:  Ledia F Hernandez; Yasuo Kubota; Dan Hu; Mark W Howe; Nuné Lemaire; Ann M Graybiel
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

Review 10.  BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases.

Authors:  Bai Lu; Guhan Nagappan; Xiaoming Guan; Pradeep J Nathan; Paul Wren
Journal:  Nat Rev Neurosci       Date:  2013-05-15       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.